Fedorchenko S V, Vovk A D, Rybalko S L
Ter Arkh. 1994;66(2):24-9.
The study included 39 patients with chronic HBeAg and DNA HBV-positive hepatitis B. 18 patients received combined therapy with prednisolone and recombinant interferon. Pretreatment investigations involved assessment of the basic virus replication by HBeAg, IgM anti-HBc, RPSHA titers, of DNA HBV concentration, alanine aminotransferase activity. The serum was examined for antibodies to alpha 2-interferon using enzyme immunoassay. The treatment resulted in disappearance of HBeAg in 70.6% of the examinees, DNA HBV in 66.6% of them. AlAT activity returned to normal in 58.8% of the patients. HBeAg and HBsAg were not registered in 5.6% of the patients. In 2 out of 4 nonresponders antibodies to alpha 2-interferon were absent. It is shown serologically that patients with initially low HBeAg, DNA HBV, high activity of AlAT, high titers IgM anti-HBc, no antibodies to alpha 2-interferon have the most favourable prognosis of the hepatitis.
该研究纳入了39例慢性HBeAg和DNA HBV阳性的乙型肝炎患者。18例患者接受了泼尼松龙和重组干扰素联合治疗。治疗前的检查包括通过HBeAg、IgM抗-HBc、RPSHA滴度评估基本病毒复制情况、DNA HBV浓度、丙氨酸转氨酶活性。采用酶免疫测定法检测血清中的α2-干扰素抗体。治疗后，70.6%的受检者HBeAg消失，66.6%的受检者DNA HBV消失。58.8%的患者丙氨酸转氨酶活性恢复正常。5.6%的患者未检测到HBeAg和HBsAg。4例无反应者中有2例缺乏α2-干扰素抗体。血清学显示，初始HBeAg、DNA HBV水平低、丙氨酸转氨酶活性高、IgM抗-HBc滴度高、无α2-干扰素抗体的患者肝炎预后最有利。
